Cost-effectiveness analysis comparing companion diagnostic tests for EGFR, ALK, and ROS1 versus next-generation sequencing (NGS) in advanced adenocarcinoma lung cancer patients

/ 2020, Evaluación de Tecnologías Sanitarias, Publicaciones Científicas / Por

L. Schluckebier,R. Caetano,O. U. Garay,G. T. Montenegro,M. Custodio,V. Aran and C. Gil Ferreira. Cost-effectiveness analysis comparing companion diagnostic tests for EGFR, ALK, and ROS1 versus next-generation sequencing (NGS) in advanced adenocarcinoma lung cancer patients. BMC Cancer. 2020;20(1):10.1186/s12885-020-07240-2.

Ir a la publicación